NASDAQ:AADI Aadi Bioscience (AADI) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free AADI Stock Alerts $1.68 -0.10 (-5.62%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.66▼$1.7550-Day Range$1.68▼$2.4452-Week Range$1.55▼$8.60Volume166,465 shsAverage Volume360,936 shsMarket Capitalization$41.24 millionP/E RatioN/ADividend YieldN/APrice Target$24.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aadi Bioscience alerts: Email Address Aadi Bioscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,368.3% Upside$24.67 Price TargetShort InterestBearish6.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$198,819 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.47) to ($2.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.51 out of 5 starsMedical Sector687th out of 908 stocksPharmaceutical Preparations Industry316th out of 423 stocks 3.3 Analyst's Opinion Consensus RatingAadi Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAadi Bioscience has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.31% of the float of Aadi Bioscience has been sold short.Short Interest Ratio / Days to CoverAadi Bioscience has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aadi Bioscience has recently increased by 16.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAadi Bioscience does not currently pay a dividend.Dividend GrowthAadi Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AADI. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Aadi Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for AADI on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Aadi Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aadi Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $198,819.00 in company stock.Percentage Held by Insiders35.80% of the stock of Aadi Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.08% of the stock of Aadi Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aadi Bioscience are expected to decrease in the coming year, from ($2.47) to ($2.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aadi Bioscience is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aadi Bioscience is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAadi Bioscience has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Aadi Bioscience Stock (NASDAQ:AADI)Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Read More AADI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AADI Stock News HeadlinesApril 4, 2024 | insidertrades.comAadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai Sells 17,772 SharesApril 26, 2024 | msn.comCongress releases candidate list for three Lok Sabha, 11 Assembly seats in Andhra PradeshApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 19, 2024 | americanbankingnews.comContrasting Statera Biopharma (NASDAQ:STAB) & Aadi Bioscience (NASDAQ:AADI)April 9, 2024 | finance.yahoo.comAadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual MeetingApril 9, 2024 | prnewswire.comAadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2024 | prnewswire.comAadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)March 16, 2024 | uk.investing.comEarnings call: Aadi Bioscience sees 60% growth in FYARRO salesApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 16, 2024 | finance.yahoo.comAADI Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comAADI Oct 2024 2.500 putMarch 16, 2024 | finance.yahoo.comAADI Jul 2024 2.500 putMarch 15, 2024 | seekingalpha.comAadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comAadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | benzinga.comAadi Bioscience Earnings PreviewMarch 14, 2024 | finance.yahoo.comAadi Bioscience Full Year 2023 Earnings: US$2.44 loss per share (vs US$2.69 loss in FY 2022)March 14, 2024 | finance.yahoo.comQ4 2023 Aadi Bioscience Inc Earnings CallMarch 13, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)March 13, 2024 | prnewswire.comAadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate UpdateMarch 12, 2024 | markets.businessinsider.comHere's what Wall Street expects from Aadi Bioscience's earnings reportMarch 6, 2024 | finance.yahoo.comAadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate UpdateMarch 5, 2024 | prnewswire.comAadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024March 2, 2024 | investing.comAadi reports durable response in PEComa treatment studyMarch 1, 2024 | marketwatch.comStocks to Watch: BioVie, Aadi BioscienceMarch 1, 2024 | marketwatch.comAadi Bioscience Shares Rise After Data Supports Fyarro as Treatment for Malignant PEComaMarch 1, 2024 | prnewswire.comAadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComaFebruary 26, 2024 | finance.yahoo.comAadi Bioscience to Present at the TD Cowen 44th Annual Healthcare ConferenceSee More Headlines Receive AADI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AADI CUSIPN/A CIK1422142 Webaadibio.com Phone(424) 473-8055FaxN/AEmployees89Year FoundedN/APrice Target and Rating Average Stock Price Target$24.67 High Stock Price Target$36.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,368.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,760,000.00 Net Margins-270.04% Pretax Margin-270.04% Return on Equity-52.53% Return on Assets-44.29% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.48 Sales & Book Value Annual Sales$24.35 million Price / Sales1.69 Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.39Miscellaneous Outstanding Shares24,550,000Free Float15,764,000Market Cap$41.24 million OptionableOptionable Beta0.62 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Neil P. Desai Ph.D. (Age 59)Founder, Secretary & Executive Chairman Comp: $1.12MDr. Loretta M. Itri F.A.C.P. (Age 74)M.D., Chief Medical Officer Comp: $805.85kMr. David J. Lennon Ph.D. (Age 53)President, CEO & Director Mr. Scott M. Giacobello CPA (Age 54)CFO, Treasurer, Investor Relations & Corporate Communications Comp: $495.56kMr. Stephen M. Rodin J.D. (Age 48)Senior VP of Legal & General Counsel Mr. Raymond G. Steitz (Age 65)Senior VP of Human Resources & Chief Human Resources Officer Mr. Bryan Ball (Age 53)Chief Quality Officer & Senior VP of Manufacturing Operations More ExecutivesKey CompetitorsNabriva TherapeuticsNASDAQ:NBRVCleneNASDAQ:CLNNNextCureNASDAQ:NXTCEledon PharmaceuticalsNASDAQ:ELDNJaguar HealthNASDAQ:JAGXView All CompetitorsInsiders & InstitutionsNeil DesaiSold 17,772 sharesTotal: $41,053.32 ($2.31/share)Neil DesaiSold 14,964 sharesTotal: $31,424.40 ($2.10/share)Neil DesaiSold 27,036 sharesTotal: $53,260.92 ($1.97/share)Decheng Capital LLCBought 526,329 shares on 2/12/2024Ownership: 2.146%Simplex Trading LLCBought 2,600 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AADI Stock Analysis - Frequently Asked Questions Should I buy or sell Aadi Bioscience stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AADI shares. View AADI analyst ratings or view top-rated stocks. What is Aadi Bioscience's stock price target for 2024? 2 brokerages have issued 12-month target prices for Aadi Bioscience's shares. Their AADI share price targets range from $5.00 to $36.00. On average, they anticipate the company's stock price to reach $24.67 in the next year. This suggests a possible upside of 1,368.3% from the stock's current price. View analysts price targets for AADI or view top-rated stocks among Wall Street analysts. How have AADI shares performed in 2024? Aadi Bioscience's stock was trading at $2.02 on January 1st, 2024. Since then, AADI shares have decreased by 16.8% and is now trading at $1.68. View the best growth stocks for 2024 here. Are investors shorting Aadi Bioscience? Aadi Bioscience saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,100,000 shares, an increase of 16.6% from the March 31st total of 943,100 shares. Based on an average daily trading volume, of 346,800 shares, the short-interest ratio is currently 3.2 days. Currently, 6.3% of the shares of the company are sold short. View Aadi Bioscience's Short Interest. When is Aadi Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our AADI earnings forecast. How were Aadi Bioscience's earnings last quarter? Aadi Bioscience, Inc. (NASDAQ:AADI) posted its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.07. The company earned $6.33 million during the quarter, compared to the consensus estimate of $6.46 million. Aadi Bioscience had a negative trailing twelve-month return on equity of 52.53% and a negative net margin of 270.04%. When did Aadi Bioscience's stock split? Aadi Bioscience shares reverse split on Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Aadi Bioscience? Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AADI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
